Lupin launches generic Wellbutrin XL Tablets in the US

Lupin Limited (Lupin) announced today the launch of its Bupropion Hydrochloride Extended-Release tablets USP (XL), 150 mg and 300 mg having received an approval from the United States Food and Drug Administration (FDA) earlier.

Lupin's Bupropion Hydrochloride Extended-Release tablets USP (XL), 150 mg and 300 mg are the AB rated generic equivalent of Valeant Pharmaceuticals North America, LLC's Wellbutrin XL® tablets, 150 mg and 300 mg. It is indicated for the treatment of major depressive disorder (MDD) and prevention of seasonal affective disorder (SAD) in adults.

Wellbutrin XL® tablets had US sales of USD 758 million (IMS MAT May 2017).

Shares of LUPIN LTD. was last trading in BSE at Rs.1185 as compared to the previous close of Rs. 1180.7. The total number of shares traded during the day was 123133 in over 2286 trades.

The stock hit an intraday high of Rs. 1194 and intraday low of 1173.5. The net turnover during the day was Rs. 145641673.

Source : Equity Bulls

Keywords